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Abstract Porphyrins related to the naturally occurring pigment 
heme were found to effectively interfere with the aggregation of 
^-amyloid peptides as determined by an immunoassay configured 
for the detection of P-amyloid oligomers. Oligomerisation of p-
amyloid is believed to be a key event in the progression of 
Alzheimer's disease. Inhibition of this aggregation is thus an 
important strategy in combating this commonest form of senile 
dementia. Evidence was also generated for hemin and hematin 
mediated protection of cultured cells against the neurotoxic 
effects of P-amyloid. These data are discussed with reference to 
the known pathology of Alzheimer's disease and the chemistry of 
porphyrins. 
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1. Introduction 
Heme is an iron protoporphyrin IX complex which is es-
sential to the function of a number of proteins. For instance, 
haemoglobin, one of the most abundant proteins in the hu-
man system, contains four non-covalently bound molecules of 
heme; these play a vital role in the transport of oxygen by this 
protein. Cytochrome, peroxidase, catalase and nitric oxide 
synthase also contain a heme moiety which, unlike the case 
of haemoglobin, is covalently bound to the protein. Physio-
logical processes involving these proteins, and mediated by 
heme, include electron transport and other redox mechanisms 
[!]■ 
As in the case of all proteinaceous material, heme-contain-
ing proteins have a definite lifetime. When of age they are 
eliminated from the organism by a series of degradation proc-
esses. Haemoglobin derived peptides have been reported to 
exhibit some opioid-like neurological activity (the so-called 
haemorphins) [2]. Thus heme released via protein degradation 
has been found to mediate neurite outgrowth [3] and cell 
development and differentiation [4]. 
Alzheimer's disease is a progressive neurodegenerative dis-
order characterised by neuronal cell death, synaptic loss and 
proteinaceous amyloid deposits at vascular and neuronal sites. 
It has been known for some time that neuronal dysfunction in 
Alzheimer's disease is initiated by the aggregation of amyloid-
p peptides, which contain 40 or 42 amino acid residues. Levels 
of P-amyloid peptide and the aggregation of P-amyloid have 
been linked to the neurodegenerative process [5,6]. These pep-
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tides are a metabolic product of the amyloid precursor protein 
(APP) [7,8]. 
Previous reports have suggested that the pathology of Alz-
heimer's disease may be linked to oxidative stress [9]. Iron is 
known to be a facilitator of oxidative stress due to the pro-
duction of hydroxyl radicals from hydrogen peroxide via the 
Fenton reaction [10-12]. Iron in the brain is mainly associated 
with ferritin and relatively very low levels are free and in 
reactive form. Nevertheless the ratio of ferritin to iron de-
creases in Alzheimer's disease with the localisation of the ef-
fect correlating with the severity of the neurological damage 
[12]. Free iron has been reported to promote P-amyloid ag-
gregation [13] whereas iron chelation has been reported to be 
protective [10]. The direct effect on amyloid production re-
mains unclear but there is evidence that the processing of 
APP shows a direct relationship with free iron levels and an 
indirect relationship with hemin and iron chelators such as 
desferrioxamine [11]. 
In our studies related to the disruption of P-amyloid aggre-
gation, we found that hemin, hematin and zinc protoporphyr-
in IX inhibited this process to a varying degree. Hemin and 
hematin were also potent inhibitors of aggregation dependent 
P-amyloid cell toxicity. These results suggest another possible 
physiological role of heme related porphyrins in reducing the 
cytotoxicity of P-amyloid aggregation and fibril formation. 
2. Materials and methods 
2.1. Materials 
Hemin, hematin, zinc protoporphyrin IX, protoporphyrin IX and 
(3-[4,5-dimethylthiaxol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
were purchased from Sigma (Poole, UK). P-Amyloid peptides 1^ 40 
and 1^ 42 were obtained from California Peptide Research Inc. (Napa, 
CA) and US Peptide Inc. (Fullerton, CA), respectively. All porphyrins 
were dissolved in dimethyl sulphoxide at 20 mM. Peptides were dis-
solved in 0.1 % acetic acid at 400 uM. Subsequent dilutions of por-
phyrins and peptides were in phosphate buffered saline containing 
0.02% (w/v) Tween-20. Appropriate vehicle controls were run in all 
experiments. 
2.2. Immunoassay for ji-amyloid aggregation 
The aggregation of P-amyloid peptides was assessed by immuno-
assay. Briefly, P-amyloid 1^ 40 or 1^ 42 was incubated at 50 (ig/ml in 
PBS/0.02% (w/v) Tween-20, overnight at 37°C, in the presence or 
absence of potential inhibitor. Peptide was then captured onto a mi-
cro titre plate pre-coated with a monoclonal antibody (2F12) raised to 
the 1-16 sequence of p-amyloid 1^10/42. Detection was via a biotiny-
lated version of the 2F12 monoclonal and binding of streptavidin-
europium (Wallac, Milton Keynes, UK) allowing quantitation by 
DELFIA (delayed enhanced lanthanide fluorescent immunoassay -
Wallac). By comparison with standard electron microscopy tech-
niques, and by using rifampicin as an inhibitor of oligomerisation 
[14], we have shown (unpublished data) that this antibody configura-
tion only recognises oligomeric P-amyloid peptide. In a typical experi-
ment, non-aggregated peptide gave a signal of approximately 20 000 
light units; the signal for aggregated peptide (24 h incubation) was 
between 600000 and 800000 light units. 
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2.3. Cell toxicity measurements 
To assess the cell toxicity potential of the aggregate(s) generated by 
overnight incubation of p-amyloid 1^ 40 (11.55 uM), IMR32 cells 
(human neuroblastoma, ECACC, Porton Down, UK) were plated 
at 6X104 cells/cm2 in a 96 well microtitre plate (Nunc). After 2 h 
attachment, potentially aggregated peptide solution (containing p-
amyloid 1^ 40 plus porphyrin, or peptide alone) was added at concen-
trations of 0.1-200 nM p-amyloid. After a further 24 h incubation, 
cell viability was assessed by an MTT assay, which depends upon the 
integrity of mitochondrial respiration for the conversion of the meta-
bolic dye MTT (3.0 mM) to a blue formazan product [15]. 
3. Results and discussion 
These results show that the iron porphyrins, hemin and 
hematin are powerful inhibitors of the P-amyloid aggregation 
process. Fig. 1 shows the dramatic fall in the maximum ag-
gregation of p-amyloid 1^40 peptide in the presence of these 
porphyrins, compared to vehicle. Replacement of iron at the 
centre of the tetrapyrrole macrocycle by zinc still inhibits the 
aggregation process. On the other hand protoporphyrin IX, 
where the iron is now replaced by two protons, is at least two 
orders of magnitude less inhibitory than hemin. We intend to 
perform further spectroscopic studies to establish the mecha-
nism of interaction of the porphyrins and p-amyloid, as this 
may provide more information about the nature of P-amyloid 
aggregation. 
We do not know the nature of this metal porphyrin-P-amy-
loid peptide complexation. However, it is interesting to note 
that P-amyloid peptides contain three histidine residues. Thus 
it is possible that the n-electrons of one of the imidazole rings 
of these amino acids are involved in bonding to the metal ion 
at the centre of the porphyrin ring, in the same way that heme 
iron in oxygen-carrying proteins complexes with an imidazole 
group of a histidine side chain [16]. Fig. 2 shows that hemin 
also inhibits the aggregation of the more hydrophobic 1—42 P-
amyloid peptide to a similar extent as that of the shorter 1^-0 
peptide. The IC50 for the inhibition of aggregation of either 
peptide by hemin is about 1 |J.M porphyrin, approximately 
one tenth of the P-amyloid peptide concentration (11.6 U.M) 
used in these experiments. The results can be interpreted as 
demonstrating that 1 mole of hemin or hematin binds either 
(i) to approximately 10 mole of P-amyloid or (ii) to an aggre-
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Fig. 1. Inhibition of aggregation of P-amyloid 1—40 by porphyrins: 
hemin (□), hematin (■), zinc protoporphyrin IX (o) and protopor-
phyrin IX (•). Vehicle corresponding to 100 u,M porphyrin only is 
shown ( A ) . Data points are the means of three experiments, deter-
mined in duplicate (error bars are ± S.E.M.). 
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Inhibition of aggregation of p-amyloid 1—40 and 1^ -2 by 
gate progenitor comprising some 10% of the total peptide 
mass, in either case preventing the formation of a toxic species 
of peptide. However, as the level of heme and related por-
phyrins in the brain has yet to be reported it is not possible to 
relate the activity described above to physiological heme lev-
els. 
A major test of the efficacy of hemin and other porphyrins 
to inhibit the aggregation of P-amyloid peptides was to add 
the porphyrin-P-amyloid incubates to human IMR32 neuro-
blastoma cells in culture. These cells are regarded as a suitable 
model for studying neurotoxic agents [17]. In the presence of 
vehicle, P-amyloid produced approximately 30% decrease in 
MTT reduction. This was attenuated in the presence of metal-
lo-porphyrin. As shown in Fig. 3, both hemin and hematin 
showed similar potency in inhibiting the production of toxic 
aggregate of P-amyloid. Hence, the data obtained in the tox-
icity assay are in excellent agreement with, and fully suppor-
tive of, the immunoassay results. The addition of hemin or 
hematin to pre-fibrillised P-amyloid had no effect on the tox-
icity response suggesting that the porphyrins had no direct 
effect on P-amyloid cell toxicity (data not shown). It is un-
likely that the reduction in cell toxicity is a result of a direct 
interaction between MTT and hemin or hematin; the concen-
tration of MTT is more than five orders of magnitude higher 
than that of the porphyrins. Similar data could not be col-
lected for protoporphyrin IX and zinc protoporphyrin IX as 
these molecules were toxic to the IMR32 cells. 
The accumulation of insoluble deposits of amyloid in the 
brain parenchyma is thought to be initiated to a large extent 
by the aggregation of hydrophobic P-amyloid peptides, con-
taining 40 or 42 amino acid residues. The latter are metabolic 
products formed from the protease cleavage of a transmem-
brane protein, the amyloid precursor protein, encoded by the 
APP gene [7,8,18]. Diffuse plaque, mostly made up of aggre-
gated p-amyloid, degenerates neurones and leads to the irre-
versible progression of Alzheimer's disease. Inhibiting either 
the aggregation or deposition of P-amyloid peptides is one of 
the therapeutic strategies that have been followed by a num-
ber of workers in attempts to combat this terrible disease 
[14,19,20]. 
From the present data it is difficult to identify whether 
hemin and hematin have any physiological role in the protec-
tion against P-amyloid toxicity in Alzheimer's disease. The 
low level of P-amyloid released from the precursor protein 
p-APP is in the soluble monomeric form, and circulates as 
such in the blood [21]. As heme-containing proteins exist 
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Fig. 3. Effects of hematin and hemin on P-amyloid 1^40 aggrega-
tion-dependent toxicity of IMR32 cells. Data points shown are the 
mean values from three experiments, carried out in triplicate (error 
bars are ± S.E.M.). 
both within and outside the brain, different levels of this and 
related porphyrins must be released during the metabolism of 
these proteins. p-Amyloid in the cerebrospinal fluid is also 
rapidly cleared into blood [22]. Moreover, the physiological 
concentration of heme appears to be age dependent. For in-
stance, it has been reported that the changes in total haemo-
globin (the biggest source of heme) concentration during ac-
tivation of brain (frontal cortex) function decreases with age 
[23]; the mean changes in elderly patients were found to be 
about 4 5 % lower than those recorded for young subjects. The 
activity of heme oxygenase-1, the enzyme which catalyses the 
degradation of heme to biliverdin and iron, also increases 
during the progression of Alzheimer's disease [24]. The latter 
phenomenon has been related to the role of oxidative stress in 
the neurofibrillary pathology of Alzheimer's disease. How-
ever, as a result of our present findings it may be possible 
to speculate that an increase in activity of heme oxygenase-1 
may have another role of decreasing the concentration of 
heme and its oxidation products, thus enhancing the P-amy-
loid aggregation process. 
References 
[1] Brzezenski, P. (1996) Biochemistry 35, 5612-5615. 
[2] Giardina, B., Mssana, I., Scatena, R. and Castagnola, M. (1995) 
Crit. Rev. Biochem. Mol. Biol. 30, 165-196. 
[3: 
[4] 
[s: 
[e: 
[?: 
[s: 
[9: 
[io: 
[ii 
[12: 
[i3; 
[14 
[15 
tie: 
[i?: 
[is: 
[is: 
po: 
[21 
[22 
[23: 
[24] 
Ishii, D.N. and Maniatis, G.M. (1978) Nature 274, 372-374. 
Abraham, N.G. (1991) Blood Rev. 5, 19-28. 
Pike, C.J., Walencewitz, A.J., Glabe, C.G. and Cotman, C.W. 
(1991) Brain Res. 563, 311-314. 
Hardy, J. and Allsop, D. (1991) Trends Pharmacol. Sci. 12, 383-
388. 
Lorenzo, A. and Yanker, B.A. (1994) Proc. Natl. Acad. Sci. USA 
91, 12243-12247. 
Iversen, L.I., Mortishire-Smith, RJ . , Pollack, S.J. and Shearman, 
M.S. (1995) Biochem. J. 311, 1-16. 
Andorn, A.C., Britton, R.S. and Bacon, B.R. (1990) Neurobiol. 
Aging 11, 316-325. 
Schubert, D. and Chevion, M. (1995) Biochem. Biophys. Res. 
Commun. 216, 702-707. 
Bodovitz, S., Falduto, M.T., Frail, D.E. and Klein, W.L. (1995) 
J. Neurochem. 64, 307-315. 
Gerlach, M., Ben-Schachar, D., Riederer, P. and Youdim, 
M.B.H. (1994) J. Neurochem. 63, 793-807. 
Mantyh, P.W., Ghilardi, J.R., Rogers, S., DeMaster, E., Allen, 
C.J., Stimson, E.R. and Maggio, J.E. (1993) J. Neurochem. 61, 
1171-1174. 
Tomiyama, T., Shoji, A., Kataoka, K.-I., Suwa, Y., Asano, S., 
Kaneko, H. and Endo, N. (1996) J. Biol. Chem. 271, 6839-6844. 
Hansen, M.B., Nielsen, S.E. and Berg, K. (1989) J. Immun. 
Methods 119, 203-210. 
Hoard, J.L. (1971) Science 192, 1295-1302. 
Williams, S.P., O'Brien, S., Whitmore, K., Purcell, W.H., Cook-
son, M.R., Pentreath, V.W. and Atterwill, C.K. (1996) In Vitro 
Toxicol. J. Mol. Cell Toxicol. 9, 83-92. 
Golde, T.E., Estus, S., Younkin, L.S., Selkoe, D.J. and Younkin, 
S.G. (1992) Science 255, 728-730. 
Pollack, S.J., Sadlere, I.J., Hawtin, S.R., Tailor, V.J. and Shear-
man, M.S. (1995) Neurosci. Lett. 197, 211-214. 
Esler, W.P., Stimson, E.R., Ghilardi, J.R., Felix, A.M., Lu, 
Y.-A., Vinters, H.V., Mantyh, P.W. and Maggio, J.E. (1997) 
Nature Biotech. 15, 258-263. 
Mattson, M.P. and Rydel, R.E. (1996) Nature 382, 674-675. 
Gersi-Egea, J.-F., Gorevic, P.D., Ghiso, J., Frangione, B., Pat-
lak, C.S. and Fenstermacher, J.D. (1996) J. Neurochem. 67, 880-
883. 
Hock, C , Muller-Spahn, F., Schuh-Hofer, S., Hofman, M., Dir-
nagl, U. and Villringer, U. (1995) J. Cereb. Blood Flow Metab. 
15, 1103-1108. 
Smith, M.A., Krishnan Kutty, R., Richey, P.L., Yan, S.-D., 
Stern, D., Chader, G.J., Wiggert, B., Petersen, R.B. and Perry, 
G. (1994) Am. J. Pathol. 145, 42-47. 
